RARE
Ultragenyx Pharmaceutical Inc.
Latest News for RARE
RBC Capital analyst Luca Issi maintained a Buy rating on Ultragenyx Pharmaceutical on April 7 and set a price target of $35.00. The company’s share......
Ultragenyx Pharmaceutical ( ($RARE) ) has issued an update. On April 2, 2026, Ultragenyx Pharmaceutical announced that the U.S. Food and Drug Admin......
The latest update is out from Ultragenyx Pharmaceutical ( ($RARE) ). On March 30, 2026, Ultragenyx Pharmaceutical announced that the U.S. Food and ......
Ultragenyx Pharmaceutical, Inc. ($RARE) announced an update on their ongoing clinical study. The phase 3 study “Adeno-Associated Virus Serotype 8-M......
Ultragenyx Pharmaceutical, Inc. ($RARE) announced an update on their ongoing clinical study. The phase 3 study “Adeno-Associated Virus Serotype 8-M......
A class action lawsuit was filed against Ultragenyx Pharmaceutical ($RARE) on February 4, 2026. The federal securities class action alleges that pl......
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Immutep (IMMP – Research Report) and Ultragenyx Pharmaceutical (R......
News data is sourced from MarketXLS API and updated regularly.
Showing 7 of 7 articles.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RARE | $23.91 | 0% | 1.97M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Ultragenyx Pharmaceutical Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW